Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | APLNR | P35414 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30482840 | 1.00 | ALDH1A1 (0.53) | ALDH1A1POLBTDP1MEN1KMT2A | |
| SCHEMBL23228992 | 0.91 | MTNR1A (0.49) | ALDH1A1POLBTDP1MEN1KMT2A | |
| SCHEMBL23617308 | 0.91 | DPP4 (0.48) | ALDH1A1POLBTDP1MEN1KMT2A | |
| SCHEMBL21455279 | 0.90 | ALDH1A1 (0.44) | ALDH1A1POLBTDP1MEN1KMT2A | |
| SCHEMBL3800298 | 0.88 | HSD17B10 (0.67) | ALDH1A1MEN1KMT2AHSD17B10PPARG | |
| SCHEMBL30104116 | 0.88 | HSD17B10 (0.67) | ALDH1A1MEN1KMT2AHSD17B10PPARG | |
| SCHEMBL24200318 | 0.87 | MTNR1A (0.50) | ALDH1A1POLBTDP1MEN1KMT2A | |
| SCHEMBL2064203 | 0.86 | DPP4 (0.48) | ALDH1A1MEN1KMT2AHSD17B10DPP4 | |
| SCHEMBL12093646 | 0.86 | PPARG (0.48) | ALDH1A1MEN1KMT2AHSD17B10TSHR | |
| SCHEMBL6246865 | 0.85 | MEN1 (0.59) | ALDH1A1MEN1KMT2AHSD17B10APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109942523-B | Benzofuran and benzofuran coumarin derivatives, and preparation method and application thereof | 华东师范大学 | 2023-06-09 | — | — | CN | disclosed |
| US-20230072867-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-03-09 | — | — | US | disclosed |
| US-11370774-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-3939658-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210221786-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-07-22 | — | — | US | disclosed |
| EP-3687506-B1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARM INC (US) | 2021-07-07 | — | — | EP | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2019195720-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| CN-109942523-A | A kind of benzofuran and benzofuran coumarin derivative and its preparation method and application | 华东师范大学 | 2019-06-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072867-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | C9, C5, C1QBP | ALDH1A1 1047/4885POLB 3620/4885TDP1 655/4885 |
| US-11370774-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | ALDH1A1 1047/4885POLB 3620/4885TDP1 655/4885 |
| US-20210221786-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | C9, C5, C1QBP | ALDH1A1 1047/4885POLB 3620/4885TDP1 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.